Clinical deployment of antibodies for treatment of melanoma

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 18-27

  Curti, Brendan D ^a   Urba, Walter J ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

Author keywords

4 1BB; CTLA 4; Melanoma; OX40; PD 1

Indexed keywords

CANCER ANTIBODY; CD137 LIGAND; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DURVALUMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; MPDL 3280A; NIVOLUMAB; OX40 LIGAND; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; TEMOZOLOMIDE; TICILIMUMAB; URELUMAB; ANTIBODY; CD134 ANTIGEN; CD137 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; TNFRSF4 PROTEIN, HUMAN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CLINICAL EVALUATION; HUMAN; MELANOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID TUMOR; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; AGONISTS; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PROCEDURES; TREATMENT OUTCOME; TRENDS;

ANTIBODIES; ANTIGENS, CD137; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOMA; MODELS, IMMUNOLOGICAL; PROGRAMMED CELL DEATH 1 RECEPTOR; RECEPTORS, OX40; TREATMENT OUTCOME;

EID: 84929386544     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.01.025     Document Type: Review

References (75)

1. Ahmadzadeh M., Johnson L.A., Heemskerk B., Wunderlich J.R., Dudley M.E., White D.E., Rosenberg S.A. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009, 114:1537-1544.
2. Alegre M.L., Noel P.J., Eisfelder B.J., Chuang E., Clark M.R., Reiner S.L., Thompson C.B. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol. 1996, 157:4762-4770.
3. Ansell S.M., Hurvitz S.A., Koenig P.A., LaPlant B.R., Kabat B.F., Fernando D., Habermann T.M., Inwards D.J., Verma M., Yamada R., Erlichman C., Lowy I., Timmerman J.M. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin. Cancer Res. 2009, 15:6446-6453.
4. Arnould L., Gelly M., Penault-Llorca F., Benoit L., Bonnetain F., Migeon C., Cabaret V., Fermeaux V., Bertheau P., Garnier J., Jeannin J.F., Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br. J. Cancer 2006, 94:259-267.
5. Ascierto P.A., Capone M., Urba W.J., Bifulco C.B., Botti G., Lugli A., Marincola F.M., Ciliberto G., Galon J., Fox B.A. The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J. Transl. Med. 2013, 11:54.
6. Ascierto P.A., Simeone E., Sileni V.C., Pigozzo J., Maio M., Altomonte M., Del Vecchio M., Di Guardo L., Marchetti P., Ridolfi R., Cognetti F., Testori A., Bernengo M.G., Guida M., Marconcini R., Mandala M., Cimminiello C., Rinaldi G., Aglietta M., Queirolo P. Clinical experience with ipilimumab 3mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J. Transl. Med. 2014, 12:116.
7. Baitsch L., Legat A., Barba L., Fuertes Marraco S.A., Rivals J.P., Baumgaertner P., Christiansen-Jucht C., Bouzourene H., Rimoldi D., Pircher H., Rufer N., Matter M., Michielin O., Speiser D.E. Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization. PLoS ONE 2012, 7:e30852.
8. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
9. Baselga J., Trigo J.M., Bourhis J., Tortochaux J., Cortes-Funes H., Hitt R., Gascon P., Amellal N., Harstrick A., Eckardt A. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2005, 23:5568-5577.
10. Baum P.R., Gayle R.B., Ramsdell F., Srinivasan S., Sorensen R.A., Watson M.L., Seldin M.F., Baker E., Sutherland G.R., Clifford K.N., et al. Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J. 1994, 13:3992-4001.
11. Bluestone J.A., Bruce D., Peterson L., Thistlethwaite J.R., Josephson M., Zeng Y., Linsley P.S., Lenschow D.J. Immunosuppressive effects of anti-CD3 MAb and soluble co-stimulatory molecules. Transplant. Proc. 1993, 25:546-547.
12. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H., Stankevich E., Pons A., Salay T.M., McMiller T.L., Gilson M.M., Wang C., Selby M., Taube J.M., Anders R., Chen L., Korman A.J., Pardoll D.M., Lowy I., Topalian S.L. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 2010, 28:3167-3175.
13. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., Pitot H.C., Hamid O., Bhatia S., Martins R., Eaton K., Chen S., Salay T.M., Alaparthy S., Grosso J.F., Korman A.J., Parker S.M., Agrawal S., Goldberg S.M., Pardoll D.M., Gupta A., Wigginton J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
14. Buenafe A.C., Weinberg A.D., Culbertson N.E., Vandenbark A.A., Offner H. V beta CDR3 motifs associated with BP recognition are enriched in OX-40+ spinal cord T cells of Lewis rats with EAE. J. Neurosci. Res. 1996, 44:562-567.
15. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004, 351:337-345.
16. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:4275-4280.
17. Curti B.D., Kovacsovics-Bankowski M., Morris N., Walker E., Chisholm L., Floyd K., Walker J., Gonzalez I., Meeuwsen T., Fox B.A., Moudgil T., Miller W., Haley D., Coffey T., Fisher B., Delanty-Miller L., Rymarchyk N., Kelly T., Crocenzi T., Bernstein E., Sanborn R., Urba W.J., Weinberg A.D. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 2013, 73:7189-7198.
18. Davis T.A., Grillo-Lopez A.J., White C.A., McLaughlin P., Czuczman M.S., Link B.K., Maloney D.G., Weaver R.L., Rosenberg J., Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 2000, 18:3135-3143.
19. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., Lennon V.A., Celis E., Chen L. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002, 8:793-800.
20. Eggermont A.M., Chiarion Sileni V., Grob J.J., Drummer R., Wolchok J.D., Schmidt H., Hamid O., Robert C., Ascierto P.A., Richards J.M., Lebbe C., Ferraresi V., Smylie M., Weber J.S., Miao M., Konto C., Gurunath R.K., De Pril V., Suciu S., Testori A. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. J. Clin. Oncol. 2014, 32(5s). (Abstr LBA9008, 2014 ASCO Annual Meeting. Chicago, IL).
21. Fecher L.A., Agarwala S.S., Hodi F.S., Weber J.S. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013, 18:733-743.
22. Ferris R.L., Jaffee E.M., Ferrone S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol. 2010, 28:4390-4399.
23. Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., Sharpe A.H. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 2009, 206:3015-3029.
24. Frederick D.T., Piris A., Cogdill A.P., Cooper Z.A., Lezcano C., Ferrone C.R., Mitra D., Boni A., Newton L.P., Liu C., Peng W., Sullivan R.J., Lawrence D.P., Hodi F.S., Overwijk W.W., Lizee G., Murphy G.F., Hwu P., Flaherty K.T., Fisher D.E., Wargo J.A. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 2013, 19:1225-1231.
25. Freeman G.J. Structures of PD-1 with its ligands: sideways and dancing cheek to cheek. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:10275-10276.
26. Gramaglia I., Weinberg A.D., Lemon M., Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses. J. Immunol. 1998, 161:6510-6517.
27. Gros A., Robbins P.F., Yao X., Li Y.F., Turcotte S., Tran E., Wunderlich J.R., Mixon A., Farid S., Dudley M.E., Hanada K., Almeida J.R., Darko S., Douek D.C., Yang J.C., Rosenberg S.A. PD-1 identifies the patient-specific CD8(+) tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 2014, 124:2246-2259.
28. Haile S.T., Bosch J.J., Agu N.I., Zeender A.M., Somasundaram P., Srivastava M.K., Britting S., Wolf J.B., Ksander B.R., Ostrand-Rosenberg S. Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80. J. Immunol. 2011, 186:6822-6829.
29. Hamid O., Sosman J.A., Lawrence D.P., Sullivan R.J., Ibrahim N., Kluger H.M., Boasberg P.D., Flaherty K., Hwu P., Ballinger M., Mokatrin A., Kowanetz M., Chen D.S., Hodi F.S. Clinical activity, safety and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). J. Clin. Oncol. 2013, 31. (abstr 9010).
30. Herbst R.S., Soria J.-C., Kowanetz M., Fine G.D., Hamid O., Gordon M.S., Sosman J.A., McDermott D.F., Powderly J.D., Gettinger S.N., Kohrt H.E.K., Horn L., Lawrence D.P., Rost S., Leabman M., Xiao Y., Mokatrin A., Koeppen H., Hegde P.S., Mellman I., Chen D.S., Hodi F.S. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014, 515:563-567.
31. Hernandez-Chacon J.A., Li Y., Wu R.C., Bernatchez C., Wang Y., Weber J.S., Hwu P., Radvanyi L.G. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J. Immunother. 2011, 34:236-250.
32. Hodi F.S., Mihm M.C., Soiffer R.J., Haluska F.G., Butler M., Seiden M.V., Davis T., Henry-Spires R., MacRae S., Willman A., Padera R., Jaklitsch M.T., Shankar S., Chen T.C., Korman A., Allison J.P., Dranoff G. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4712-4717.
33. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette G.P., Hogg D., Ottensmeier C.H., Lebbe C., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., Urba W.J. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
34. Hoos A., Eggermont A.M., Janetzki S., Hodi F.S., Ibrahim R., Anderson A., Humphrey R., Blumenstein B., Old L., Wolchok J. Improved endpoints for cancer immunotherapy trials. J. Natl. Cancer Inst. 2010, 102:1388-1397.
35. Huang R.R., Jalil J., Economou J.S., Chmielowski B., Koya R.C., Mok S., Sazegar H., Seja E., Villanueva A., Gomez-Navarro J., Glaspy J.A., Cochran A.J., Ribas A. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin. Cancer Res. 2011, 17:4101-4109.
36. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:12293-12297.
37. Kitano S., Postow M.A., Ziegler C.G., Kuk D., Panageas K.S., Cortez C., Rasalan T., Adamow M., Yuan J., Wong P., Altan-Bonnet G., Wolchok J.D., Lesokhin A.M. Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. Cancer Immunol. Res. 2014, 2:812-821.
38. Larkin J., Ascierto P.A., Dréno B., Atkinson V., Liszkay G., Maio M., Mandalà M., Demidov L., Stroyakovskiy D., Thoma L., de la Cruz-Marino L., Dutriaux C., Garbe C., Sovak M.A., Chang I., Choong N., Hack S.P., McArthur G.A., Ribas A. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 2014, 371:1867-1876.
39. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
40. Lebbe C., Weber J.S., Maio M., Neyns B., Harmankaya K., Hamid O., O'Day S.J., Konto C., Cykowski L., McHenry M.B., Wolchok J.D. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann. Oncol. 2014, 25:2277-2284.
41. Lin G.H., Liu Y., Ambagala T., Kwon B.S., Ohashi P.S., Watts T.H. Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS ONE 2010, 5:e11003.
42. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E., de Braud F., Larkin J., Garbe C., Jouary T., Hauschild A., Grob J.J., Chiarion Sileni V., Lebbe C., Mandalà M., Milward M., Arance A., Bondarenko I., Haanen J.B.A.G., Hansson J., Utikal J., Ferraresi V., Kovalenko N., Mohr P., Probachai V., Schadendorf D., Nathan P., Robert C., Ribas A., DeMarini D.J., Irani J.G., Casey M., Ouellet D., Martin A.-M., Le N., Patel K., Flaherty K. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 2014, 371:1877-1888.
43. Mardiros A., Dos Santos C., McDonald T., Brown C.E., Wang X., Budde L.E., Hoffman L., Aguilar B., Chang W.C., Bretzlaff W., Chang B., Jonnalagadda M., Starr R., Ostberg J.R., Jensen M.C., Bhatia R., Forman S.J. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood 2013, 122:3138-3148.
44. Palazon A., Teijeira A., Martinez-Forero I., Hervas-Stubbs S., Roncal C., Penuelas I., Dubrot J., Morales-Kastresana A., Perez-Gracia J.L., Ochoa M.C., Ochoa-Callejero L., Martinez A., Luque A., Dinchuk J., Rouzaut A., Jure-Kunkel M., Melero I. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res. 2011, 71:801-811.
45. Paterson D.J., Jefferies W.A., Green J.R., Brandon M.R., Corthesy P., Puklavec M., Williams A.F. Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol. Immunol. 1987, 24:1281-1290.
46. Pennock G.K., Waterfield W., Wolchok J.D. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?. Am. J. Clin. Oncol. 2012, 35:606-611.
47. Postow L., Crisona N.J., Peter B.J., Hardy C.D., Cozzarelli N.R. Topological challenges to DNA replication: conformations at the fork. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:8219-8226.
48. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., Mu Z., Rasalan T., Adamow M., Ritter E., Sedrak C., Jungbluth A.A., Chua R., Yang A.S., Roman R.A., Rosner S., Benson B., Allison J.P., Lesokhin A.M., Gnjatic S., Wolchok J.D. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 2012, 366:925-931.
49. Ribas A., Kefford R., Marshall M.A., Punt C.J., Haanen J.B., Marmol M., Garbe C., Gogas H., Schachter J., Linette G., Lorigan P., Kendra K.L., Maio M., Trefzer U., Smylie M., McArthur G.A., Dreno B., Nathan P.D., Mackiewicz J., Kirkwood J.M., Gomez-Navarro J., Huang B., Pavlov D., Hauschild A. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 2013, 31:616-622.
50. Ribas A., Tumeh P.C. The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade. Clin. Cancer Res. 2014, 20:4982-4984.
51. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., Weber J.S., Joshua A.M., Hwu W.J., Gangadhar T.C., Patnaik A., Dronca R., Zarour H., Joseph R.W., Boasberg P., Chmielowski B., Mateus C., Postow M.A., Gergich K., Elassaiss-Schaap J., Li X.N., Iannone R., Ebbinghaus S.W., Kang S.P., Daud A. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
52. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., Hassel J.C., Rutkowski P., McNeil C., Kalina-Warzocha E., Savage K.J., Hernberg M.M., Lebbé C., Charles J., Mihalcioiu C., Chiarion-Sileni V., Mauch C., Cognetti F., Arance A., Schmidt H., Schadendorf D., Gogas H., Lundgren-Eriksson L., Horak C., Sharkey B., Waxman I.M., Atkinson V., Ascierto P.A. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 2015, 372:320-330.
53. Robert C., Bondarenko T.L., O'Day S., Weber J., Garge C., Lebbe C., Baurain J.F., Testori A., Grob J.J., Davidson N., Richards J., Maio M., Hauschild A., Miller W.H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T.T., Humphrey R., Hoos A., Wolchok J.D. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 2011, 364:2517-2526.
54. Robert L., Tsoi J., Wang X., Emerson R., Homet B., Chodon T., Mok S., Huang R.R., Cochran A.J., Comin-Anduix B., Koya R.C., Graeber T.G., Robins H., Ribas A. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin. Cancer Res. 2014, 20:2424-2432.
55. Schadendorf D., Hodi F.S., Robert C., Weber J.S., Margolin K., Hamid O., Chen T.T., Berman D.M., Wolchok J.D. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. J. Clin. Oncol. 2015, 20. JCO.2014.56.2736 [Epub ahead of print].
56. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., Korman A.J. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res. 2014, 1:32-42.
57. Seung S.K., Curti B.D., Crittenden M., Walker E., Coffey T., Siebert J.C., Miller W., Payne R., Glenn L., Bageac A., Urba W.J. Phase 1 study of stereotactic body radiotherapy and interleukin-2-tumor and immunological responses. Sci. Transl. Med. 2012, 4:(137 ra74).
58. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., Roddie C., Henry J.Y., Yagita H., Wolchok J.D., Peggs K.S., Ravetch J.V., Allison J.P., Quezada S.A. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 2013, 210:1695-1710.
59. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 2001, 344:783-792.
60. Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., Walsh L.A., Postow M.A., Wong P., Ho T.S., Hollmann T.J., Bruggeman C., Kannan K., Li Y., Elipenahli C., Liu C., Harbison C.T., Wang L., Ribas A., Wolchok J.D., Chan T.A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 2014, 371:2189-2199.
61. Tarhini A.A., Edington H., Butterfield L.H., Lin Y., Shuai Y., Tawbi H., Sander C., Yin Y., Holtzman M., Johnson J., Rao U.N., Kirkwood J.M. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE 2014, 9:e87705.
62. Taube J.M., Klein A., Brahmer J.R., Xu H., Pan X., Kim J.H., Chen L., Pardoll D.M., Topalian S.L., Anders R.A. Association of PD-1 PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 2014, 20:5064-5074.
63. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., Leming P.D., Spigel D.R., Antonia S.J., Horn L., Drake C.G., Pardoll D.M., Chen L., Sharfman W.H., Anders R.A., Taube J.M., McMiller T.L., Xu H., Korman A.J., Jure-Kunkel M., Agrawal S., McDonald D., Kollia G.D., Gupta A., Wigginton J.M., Sznol M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
64. Topp M.S., Gökbuget N., Zugmaier G., Klappers P., Stelljes M., Neumann S., Viardot A., Marks R., Diedrich H., Faul C., Reichle A., Horst H.A., Brüggermann M., Wessiepe D., Holland C., Alekar S., Mergen N., Einsele H., Hoelzer D., Bargou R.C. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab show hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J. Clin. Oncol. 2014, 32:4134-4140.
65. Urba W.J., Ewel C., Kopp W., Smith J.W., Steis R.G., Ashwell J.D., Creekmore S.P., Rossio J., Sznol M., Sharfman W., et al. Anti-CD3 monoclonal antibody treatment of patients with CD3-negative tumors: a phase IA/B study. Cancer Res. 1992, 52:2394-2401.
66. Vetto J.T., Lum S., Morris A., Sicotte M., Davis J., Lemon M., Weinberg A. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am. J. Surg. 1997, 174:258-265.
67. Weber J., Thompson J.A., Hamid O., Minor D., Amin A., Ron I., Ridolfi R., Assi H., Maraveyas A., Berman D., Siegel J., O'Day S.J. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin. Cancer Res. 2009, 15:5591-5598.
68. Weber J.S., Kahler K.C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 2012, 30:2691-2697.
69. Weber J.S., Kudchadkar R.R., Yu B., Gallenstein D., Horak C.E., Inzunza H.D., Zhao X., Martinez A.J., Wang W., Gibney G., Kroeger J., Eysmans C., Sarnaik A.A., Chen Y.A. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. J. Clin. Oncol. 2013, 31:4311-4318.
70. Weber J.S., Minor D.R., D'Angelo S., Hodi F.S., Gutzmer R., Neyns B., Hoeller C., Khushalani N.I., Miller W.H., Grob J., Lao C., Linette G., Grossman K., Hassel J., Lorigan P., Maio M., Sznol M., Lambert A., Yang A., Larkin J. LBA3_PR-a phase 3 randomized, open label study of nivolumab (anti-PD01; BMS 926558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. Ann. Oncol. 2014, 25:1-41.
71. Weinberg A.D., Lemon M., Jones A.J., Vainiene M., Celnik B., Buenafe A.C., Culbertson N., Bakke A., Vandenbark A.A., Offner H. OX-40 antibody enhances for autoantigen specific V beta 8.2+ T cells within the spinal cord of Lewis rats with autoimmune encephalomyelitis. J. Neurosci. Res. 1996, 43:42-49.
72. Weinberg A.D., Rivera M.M., Prell R., Morris A., Ramstad T., Vetto J.T., Urba W.J., Alvord G., Bunce C., Shields J. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J. Immunol. 2000, 164:2160-2169.
73. Wilmott J.S., Long G.V., Howle J.R., Haydu L.E., Sharma R.N., Thompson J.F., Kefford R.F., Hersey P., Scolyer R.A. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin. Cancer Res. 2012, 18:1386-1394.
74. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., Segal N.H., Ariyan C.E., Gordon R.A., Reed K., Burke M.M., Caldwell A., Kronenberg S.A., Agunwamba B.U., Zhang X., Lowy I., Inzunza H.D., Feely W., Horak C.E., Hong Q., Korman A.J., Wigginton J.M., Gupta A., Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
75. Yang J.C., Hughes M., Kammula U., Royal R., Sherry R.M., Topalian S.L., Suri K.B., Levy C., Allen T., Mavroukakis S., Lowy I., White D.E., Rosenberg S.A. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J. Immunother. 2007, 30:825-830.